Physician profile
Shahnaz Ali
NPI 1922020478
$12,844.93
in general payments reported to CMS, 2019-2025
74 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $903 · 2021: $1,589 · 2022: $2,476 · 2023: $1,741 · 2024: $1,838 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,942 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,942.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.21 | 2019-2025 | Vraylar, Viberzi |
| Astellas Pharma US INC | $939.98 | 2019-2025 | Veozah |
| Acadia Pharmaceuticals INC | $635.37 | 2019-2024 | Nuplazid |
| Pfizer INC. | $604.94 | 2019-2025 | |
| Lilly USA, LLC | $604.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $576.21 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $514.92 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $502.08 | 2019-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $496.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $494.10 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $481.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $392.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $392.35 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $324.47 | 2023-2025 | Gemtesa, Aptiom, Myfembree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.91 | 2019-2024 | Ofev, Jardiance |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahnaz Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.